Sector News

Ferring appoints Aaron Graff to Executive Board

June 2, 2017
Life sciences

Ferring Pharmaceuticals announced today that Aaron Graff has been appointed Executive Vice President and Chief Commercial Officer and made a member of the Ferring Group Executive Board, effective immediately.

Aaron Graff joined Ferring in 2002 as Vice President Global Marketing, Business Development, and Medical Affairs, based in Copenhagen, Denmark. After leading the acquisition and integration of Israeli biopharmaceutical company BTG in 2005, he relocated his team to the newly established Ferring International Center in Saint-Prex, Switzerland, where he was promoted to Senior Vice President, Asia Region and Global Marketing. Since 2010, Graff has led Ferring’s U.S. operations from its U.S headquarters in New Jersey, first as Chief Operating Officer and since 2016 as Chief Executive Officer.

“Under Aaron’s leadership in the United States, our U.S. business grew at double-digit rates,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “His broad, global professional experience and track record make him uniquely qualified for this important role.”

Prior to joining Ferring, Graff worked at Bristol-Myers Squibb for over 17 years in a variety of sales, marketing and commercial operations management positions.

Source: Ferring Pharmaceuticals

Related News

September 30, 2020

Johnson & Johnson signs on Michigan’s Grand River to help with COVID-19 vaccine finishing work

Life sciences

With all eyes on the hunt for a COVID-19 vaccine, drugmakers like New Jersey’s Johnson & Johnson are scouring the market for manufacturing partners to help meet what would be […]

September 30, 2020

Takeda taps Elektrofi’s microparticle delivery platform for potential subq plasma offerings

Life sciences

Takeda has joined forces with drug delivery specialist Elektrofi to see whether the biotech’s microparticle formulation technology could enable simpler dosing with plasma-derived therapies. Takeda will assess Elektrofi’s drug delivery platform using […]

September 29, 2020

Heart to heart: Novo Nordisk teams with ACC to open diabetes discussion

Life sciences

Novo Nordisk wants the heart disease community to join the diabetes conversation. As Type 2 diabetes drugs nab approvals for reduced cardiovascular risks—including Novo’s own Ozempic and Victoza—the need to […]